Despite the prevalence of TP53 mutations in cancer, many retrospective studies have failed to identify associations between TP53 abnormalities (e.g., mutations, amplifications) and clinicopathologic phenotypes5, and the lack of well-established clinical significance between patient outcomes and TP53 status has become one of the most controversial topics in cancer research, including GC and colorectal cancer (CRC)1, 5, 6, 7. Here, TP53 is linked to colorectal cancer.